Celltrion
068270.KS
96,67 €
Share price
-0.19%
Change (1 day)
-19.64%
Change (1 year)
Categories
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.
Revenue for Celltrion (068270.KS)
Revenue in 2024 (TTM): €2.39 Billion
According to Celltrion
's latest financial reports the company's current revenue (TTM 
) is €2.26 Billion. an increase over the revenue in the year 2023 that were of €1.49 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Celltrion from 2008 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | €2.47 B | 66.11% |
| 2023 | €1.49 B | -8.69% |
| 2022 | €1.63 B | 12.43% |
| 2021 | €1.45 B | 12.36% |
| 2020 | €1.29 B | 49.47% |
| 2019 | €0.86 B | 10.92% |
| 2018 | €0.78 B | 10.08% |
| 2017 | €0.70 B | 28.22% |
| 2016 | €0.55 B | 15.47% |
| 2015 | €0.47 B | 29.62% |
| 2014 | €0.36 B | 146.52% |
| 2013 | €0.14 B | -38.27% |
| 2012 | €0.24 B | |
| 2010 | €0.11 B | 44.99% |
| 2009 | €81.32 M | 57.94% |
| 2008 | €51.49 M |